BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Stroke clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for stroke: 197 (149 sponsors; 34 newly posted in the last 180 days, 9 stopped in the last 180 days; 20 new-entrant sponsors). Momentum score 13.2, rank 52 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 10, Phase 2 34, Phase 3 24, Phase 4 8, N/A 121.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Regeneron Pharmaceuticals REGN | 4 | P3 3, P2 1 | 2 | 1 |
| Eli Lilly and Company LLY | 3 | P3 2, P2 1 | 1 | 0 |
| Novartis Pharmaceuticals NVS | 2 | P3 2 | 0 | 0 |
| CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | 2 | NA 1, P3 1 | 0 | 1 |
| Pharmazz, Inc. | 2 | P4 1, P3 1 | 0 | 1 |
| Biocells (Beijing) Biotech Co.,Ltd | 1 | P3 1 | 0 | 0 |
| Boehringer Ingelheim | 1 | P3 1 | 0 | 0 |
| Corxel Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| Cytopeutics Sdn. Bhd. | 1 | P3 1 | 0 | 1 |
| DiaMedica Therapeutics Inc DMAC | 1 | P3 1 | 0 | 1 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 0 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Khondrion BV | 1 | P3 1 | 0 | 0 |
| Merz Pharmaceuticals GmbH | 1 | P3 1 | 0 | 0 |
| Moleac Pte Ltd. | 1 | P3 1 | 0 | 0 |
| Shanghai Hutchison Pharmaceuticals Limited | 1 | P3 1 | 0 | 0 |
| Shin Poong Pharmaceutical Co. Ltd. | 1 | P3 1 | 0 | 1 |
| Supergene, LLC | 1 | P3 1 | 0 | 0 |
| Tasly Biopharmaceuticals Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Tatchempharmpreparaty, JSC | 1 | P3 1 | 0 | 0 |
| Boston Scientific Corporation BSX | 4 | NA 4 | 0 | 0 |
| Neuralink Corp | 4 | NA 4 | 1 | 0 |
| Abbott Medical Devices | 3 | NA 3 | 0 | 0 |
| iVascular S.L.U. | 3 | NA 3 | 0 | 0 |
| AcQumen Medical, Inc. new entrant | 2 | NA 2 | 2 | 0 |
New-entrant sponsors: Jiangsu Simcere Pharmaceutical Co., Ltd., Tasly Biopharmaceuticals Co., Ltd., AcQumen Medical, Inc..
Recently stopped trials
- NCT06961344 Tisento Therapeutics - terminated: Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not rela An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
- NCT06168942 Jaguar LAA, Inc. - suspended: Potential unwrapping of the LAA post implant with clinically significant leaks. A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
- NCT05147792 Conformal Medical, Inc - suspended: Enrollment has been temporarily suspended out of an abundance of caution and in close consultation with trial leadership and regulatory bodi The CONFORM Pivotal Trial
- NCT02928497 Boston Scientific Corporation - terminated: The enrollment was prematurely terminated on October 15, 2020, with 481 randomized patients. As discussed in the ASAP-TOO Update Meeting hel Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
- NCT03545607 Healios K.K. - terminated: Sponsor's decision MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
- NCT05547438 NeuroTrauma Sciences, LLC - terminated: a second generation product was found to be more relevant for development Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
- NCT03346538 Shionogi - terminated: Business objectives have changed. Dose Finding Study of MCI-186 in Acute Ischemic Stroke
- NCT04815967 Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC - terminated: Company/sponsor business decision; not due to or related to any safety concerns Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
- NCT04099667 Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC - terminated: Company/sponsor business decision; not due to or related to any safety concerns Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2/P3 | Cytopeutics Sdn. Bhd. | NCT06129175 UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX) | Acute Ischemic Stroke | recruiting | 80 |
| 2026-12 est. | P2/P3 | DiaMedica Therapeutics Inc DMAC | NCT05065216 Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | Acute Stroke; Ischemic Stroke; Stroke | recruiting | 728 |
| 2026-12 est. | P2 | NoNO Inc. | NCT06403267 NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy | Acute Ischemic Stroke | recruiting | 600 |
| 2026-12-10 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05686642 Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke | Acute Ischemic Stroke | recruiting | 300 |
| 2026-12-30 est. | P2 | ThromBio Pty. Ltd. | NCT06813651 Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion | Ischemic Stroke; Tandem Occlusion | recruiting | 78 |
| 2026-12-31 est. | P2 | Lumosa Therapeutics Co., Ltd. | NCT05198323 A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT | Acute Ischemic Stroke | active not recruiting | 66 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Changzhou Qianhong Bio-pharma Co., Ltd. | NCT07396337 Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. | Acute Ischemic Stroke | recruiting | 320 |
| 2026-10-29 | P2 | Tisento Therapeutics | NCT06961344 An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) | Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | terminated | 37 |
| 2026-10-18 est. | P2 | Kunming Pharmaceuticals, Inc. | NCT07279493 Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke | Acute Ischemic Stroke | recruiting | 300 |
| 2026-10-15 est. | P3 | Janssen Research & Development, LLC | NCT05702034 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | Ischemic Stroke; Ischemic Attack, Transient | active not recruiting | 12523 |
| 2026-09-23 | P2 | EIP Pharma Inc | NCT06987643 A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke | completed | 45 |
| 2026-09-17 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07233070 HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. | Acute Ischemic Stroke | completed | 210 |
| 2026-08 est. | P2 | Shanghai QuietD Biotechnology Co., Ltd. | NCT07581210 Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy | Acute Ischemic Stroke | recruiting | 120 |
| 2026-07 est. | P3 | ZZ Biotech, LLC | NCT05484154 Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke | Ischemic Stroke | withdrawn | |
| 2026-06-29 | P2 | Tisento Therapeutics | NCT06402123 A Phase 2b Study of Zagociguat in Patients With MELAS | Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | completed | 43 |
| 2026-06-15 | P2 | Shionogi | NCT05953480 A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 680 |
| 2026-06-12 | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT07205328 A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 360 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "stroke"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.